Sertraline → Sertraline, cis-(-)-
反応式
[CH3:1][NH:2][C@@H:3]1[C:8]2[CH:9]=[CH:10][CH:11]=[CH:12][C:7]=2[C@H:6]([C:13]2[CH:14]=[CH:15][C:16]([Cl:20])=[C:17]([Cl:19])[CH:18]=2)[CH2:5][CH2:4]1.ClC1C=C(C(C2C=CC=CC=2)CCC(O)=O)C=CC=1Cl.ClC1C=C(C2C3C(=CC=CC=3)C(=O)CC2)C=CC=1Cl>>[CH3:1][NH:2][C@H:3]1[C:8]2[C:7](=[CH:12][CH:11]=[CH:10][CH:9]=2)[C@@H:6]([C:13]2[CH:14]=[CH:15][C:16]([Cl:20])=[C:17]([Cl:19])[CH:18]=2)[CH2:5][CH2:4]1参加物
実験手順
As previously indicated, the 4-(3,4-dichlorophenyl)-4-phenylbutanoic acid final product afforded by the process of this invention is a valuable intermediate that ultimately leads to the antidepressant agent known as sertraline or cis-(1S) (4S)-N-methyl-4-(3,4-dichlorophenyl)-1, 2,3,4-tetrahydro-1-naphthaleneamine as disclosed in the previously discussed prior art. More specifically, 4-(3,4-dichlorophenyl)-4-phenylbutanoic acid is first converted to 4-(3,4-dichlorophenyl)-3, 4-dihydro-1-(2H)-naphthalenone and then finally to racemic cis-N-methyl-4-(3,4-dichlorophenyl)-1, 2,3,4-tetrahydro-1-naphthaleneamine prior to ultimately yielding the desired cis-(1S) (4S)-N-methyl-4-(3,4-dichlorophenyl)-1, 2,3,4-tetrahydro-1-naphthaleneamine by the multi-step method of the prior art process as earlier described by W.M. Welch, Jr. et al. in U.S. Pat. No. 4,536,518 and the Journal of Medicinal Chemistry, Vol. 27, No. 11, p. 1508 (1984).
出典と根拠
- ORDレコード
- ord-99645623274745aa8584a0a30c4cef90
- 出典データセット
- uspto-grants-1988_10
- 特許番号
- US04777288
反応ノート
読み込み中…